JPMorgan raised the firm’s price target on Cellebrite (CLBT) to $24 from $22 and keeps an Overweight rating on the shares. The firm updating security software price targets for 2025 to reflect its view of current and anticipated market conditions.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter